Gongwin Business Summary

Gongwin Biopharm Holdings Co., Ltd. (6617.TWO) is a clinical-stage biopharmaceutical company that generates revenue through the commercialization and licensing of its proprietary Minimally Invasive Targeted Tumor Ablation (MITTA) technology. The company’s business model is centered on the intratumoral injection of its lead active pharmaceutical ingredient, para-toluene sulfonamide (PTS), which induces rapid necrosis in solid tumors while sparing healthy tissue. Its primary revenue driver is PTS302 (marketed as Purocenta), which is approved in China for treating severe malignant airway obstructions in non-small cell lung cancer (NSCLC). Gongwin’s broader pipeline includes PTS100 for hepatocellular carcinoma, PTS-02 for adenoid cystic carcinoma, and PTS500 for malignant pleural effusion, alongside a growing veterinary oncology segment (GWA101/103) targeting companion animals. Within the Taiwanese biotech sector, Gongwin competes with oncology-focused peers such as OBI Pharma (4174), TaiMed Biologics (4147), and Senhwa Biosciences (6492), distinguishing itself through its unique chemical ablation niche compared to traditional systemic therapies or biologics. The company was co-founded by Dr. Rocky Shih and Dr. John Wu, who pioneered the development of the PTS molecule. As of March 2026, the leadership team is headed by Chairman Lester John Wu (also known as Chonghan Wu), who brings over 20 years of experience in the biotechnology and pharmaceutical industries across the Asia-Pacific region. Mao-Yuan (Morrice) Lin serves as the General Manager and Director, overseeing global financial operations and the company's strategic expansion into the U.S. and Southeast Asian markets. The executive team is supported by a recently restructured board of directors, including Shao-Feng Chien and Chi-Hsiu Liu, and has secured significant external backing, notably a $50 million investment from Fund A in 2025 to capitalize its U.S. subsidiary for advanced clinical trials.